94 60.18 ± 29.92 0.358* 0.243** 0.735*** VEGF ( pg/ml ) 25.54 ± 19.13 27.92 ± 19.13 30.39 ± 24.19 0.365* 0.436** 0.976*** *Normal vs CINII~III; ** Normal vs CC; *** CINII~III vs CC P of the three groups:IL-6: P = 0.000, F = 17.712; TGFβ: P = 0.000, F = 21.671; IL-10: P = 0.450, F = 0.802; VEGF: P = 0.601, F = 0.511 Figure 4 The functional immunophenotypings of DCs in patients with CC, CIN and controls. Figure 5 The serum TGFβ secretion in patients with CC, CIN and

controls. Similar observations were found for TGF-β. The level of TGF-β in the CIN group (6.41 ± 5.20 pg/mL) was higher in comparison to the healthy individuals (5.60 ± 4.83 pg/mL) and highest in patients with cervical carcinoma (18.22 ± 12.18 pg/mL). It was significantly higher (P < 0.05) between the CC groups and the controls. It was also significantly higher (P < 0.05) between the CC groups Liproxstatin-1 mouse and the CIN group. But no significant differences (P > 0.05) between the CIN groups and the controls were observed. No obvious variation was PF-573228 manufacturer observed in levels of IL-10 and VEGF. The levels of IL-10 and VEGF in the CIN group (IL-10: 57.95 ± 32.94 pg/mL; VEGF: 27.92 ± 19.13 pg/mL) were higher in comparison to the healthy individuals

(IL-10: 52.69 ± 28.27 pg/mL; VEGF: 25.54 ± 19.13 pg/mL) and highest in patients with cervical carcinoma (IL-10: 60.18 ± 29.92 pg/mL; VEGF: 30.39 ± 24.19 pg/mL). There were no significant differences between any two groups. Patients with CC and CIN thus have higher levels of these suppressive MK-0457 cytokines than the controls. Discussion The ability of tumor cells to evade host immune system control can be ascribed to many mechanisms, including deletion this website of tumor-specific cytotoxic T-lymphocytes and recruitment of regulatory T-lymphocytes and inhibitory cell types. In addition, cancer patients may present a defect in the host immune system [4, 30, 31]. One of the targets of this defect is represented by professional APC; an impaired DC function in cancer patients has been reported by several groups [32–34].

Tumors achieve this suppressive effect on DC by secreting tumor-derived factors, as recently described [27, 29, 35]. Human DCs are phenotypically and functionally heterogeneous. The ability to identify and enumerate DCs and their subsets in tumor tissue and in the peripheral circulation of patients with cancer appears to be fundamental for the understanding of the role of these cells in the host antitumor responses. Firstly, we showed that patients with cervical carcinoma and CIN exhibit a significant decrease in the absolute number of circulating DCs when compared to healthy controls. The reduction affects both of the two main subsets of DCs circulating in the PB. The most striking observation of the current study was a relative decrease in the percentage of CD11c+DC cells (DC1) in the peripheral circulation of CC patients. The percentage of DC1 was significantly lower (P < 0.05) in patients with cervical carcinoma than in the CIN and control groups.